At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
AMG 714 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Apr 8, 2020·Updated Apr 21, 2026
In Brief
A Phase 2 clinical trial evaluating AMG 714, Placebo, and 1 other intervention for Vitiligo. Completed, enrolled 60 participants across 7 sites.
Detailed Summary
This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitiligo
CountriesUnited States
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartDec 2020
Primary CompletionOct 2024
Study CompletionApr 2025
TodayJul 2026
First PostedApr 8, 2020
Enrollment StartDec 11, 2020
Primary CompletionOct 16, 2024
Study CompletionApr 2, 2025
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.2 years ago
Interventions
AMG 714biological
anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
Placebobiological
Placebo for AMG 714
nbUVB phototherapyprocedure
Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.